




MEMPHASYS
REPRODUCTIVE BIOTECHNOLOGY

ASX: MEM | INVESTOR PRESENTATION · 2026

A New Era of Commercial Execution

Anchored by Monash IVF

The largest commercial agreement in company history



Why Memphasys, why now

1

Largest deal ever

Monash IVF international agreement

2

Committed \$2M contracted revenue FY26

Delivered \$2.5M+

3

Commercial deals signed

Europe, UK, MENA, SE-Asia & Australia

4

Recurring revenue

Console + cartridge consumables model

5

A\$106k record quarter

First multi-market revenue (Mar-26)

6

Regulatory cleared

CE mark, TGA, MHRA & key intl. markets

7

Rich near-term pipeline

Advancing across regions

8

Pathway to scale

Revenue growth & margin expansion

THE OPPORTUNITY

A large, growing market — and a better way

60,000+

Fresh IVF cycles performed in Australia every year

~21%

Monash IVF's share of the Australian stimulated-IVF market

10+ markets

Felix™ positioned across AU, Europe, UK, MENA, India, Japan & SE-Asia

MEMPHASYS · ASX: MEM

THE PROBLEM TODAY

Conventional sperm selection relies on centrifugation — slow, manual, and potentially damaging to delicate sperm cells and DNA.

THE FELIX DIFFERENCE

An automated, electrophoretic system that gently isolates the most viable sperm — fast, standardised and clinic-ready.

A large, fast-growing global prize

IVF demand is large and growing ~9% a year — and Felix sells into the recurring consumable layer of every cycle.

TAM · Global IVF market

~US\$30B today → ~US\$65B+ by 2034 · ~9% CAGR

SAM · Sperm preparation in every cycle

Millions of IVF / ICSI cycles a year — each requires sperm processing

SOM · Signed-market beachhead

Australia, Europe, MENA, India, Japan & SE Asia

Sources: industry IVF-market reports, 2025–26. Market figures indicative — confirm against preferred sources before distribution.

Felix™ — automated sperm selection

Felix™ replaces manual centrifugation with an automated, single-use cartridge system — isolating the healthiest, most motile sperm in one gentle run.



Single-use Felix™ cartridge



Console + cartridge in clinic use

Fast · Gentle · Standardised · Recurring cartridge model

Why Felix™ wins — and what protects it

	Felix™	Centrifugation	Swim-up	Microfluidic chip
Automated & standardised	Yes	No	No	No
Gentle — protects sperm DNA	Yes	No	Partial	Partial
Fast, single-run	Yes	No	No	Partial
Recurring consumable model	Yes	No	No	Yes

OUR MOAT — WHAT PROTECTS FELIX™

Patent-protected platform

Proprietary electrophoresis + size-exclusion separation.

Cartridge know-how

Proprietary membrane chemistry & manufacturing.

Regulatory approvals

TGA/ARTG, Europe & international market access.

Validated & embedded

Monash trial + lab-workflow switching costs.

National supply agreement with Monash IVF

Exclusive 12-month national supply agreement — the largest commercial arrangement in Memphasys' history.

Felix rolls out across Monash IVF's national clinic network following a successful three-month initial deployment — establishing an anchor reference customer in Australia.

22

Monash IVF clinics
across mainland
Australia

~21%

Share of the Australian
stimulated-IVF market

12,085

Stimulated IVF cycles in
FY2025

Recurring

Cartridge + console
revenue, quarterly orders

Independently validated by Monash IVF



Felix™ in use in the embryology laboratory

Felix™'s performance has been confirmed in a pivotal, multi-site clinical trial led by Monash IVF — with peer-reviewed publication expected.



Pivotal trial completed (2025)

Multi-site Monash IVF trial confirmed Felix's performance vs conventional methods.



Decade-long collaboration

Built on 10+ years of joint development and optimisation with Monash IVF.



Global KOL evidence

Key-opinion-leader study across 13 leading IVF centres in 8 countries.

Approvals secured across key markets



Australia

TGA approval secured and Felix listed on the ARTG — cleared two months ahead of schedule, opening domestic sales.



Europe & UK

CE Mark secured (Dec 2025) — cleared for commercial sale across Europe, underpinning multi-year contracted revenue. MHRA registration achieved. Cleared for sale in the UK



International

Market access secured across MENA, India, Japan and Southeast Asia.

Manufacturing, supply-chain and quality systems are established and ready to support national and international scale-up.

Anchored by Monash — scaling worldwide

Signed, revenue-generating supply agreements — not trials. The majority of partners have already placed repeat orders, confirming a scalable recurring-revenue model.

EUROPE

CFA Italia (Italy)
~A\$925K min · multi-year
Market entry post-CE Mark
(Dec 2025); clinics
onboarding.

MENA

ITL — exclusive 5-yr
supply
~A\$390K min
1,800 cartridges in 2
quarters
Qatar: 2nd console +
1,000-cartridge order.

Repeat orders ✓

ASIA

Vietnam — 2-yr, A\$530K
Vietnam approval
expected Aug 2026.
Japan — reference market

Repeat orders ✓ (Japan)

INDIA

Andro Diagnostics — non-
exclusive 5-yr
Yr 1: 1,800 cartridges
(~A\$98.8k)
450 cartridges / quarter
Pending CDSCO (~6
months).

A recurring, razor-and-blade model



Felix™ console + single-use cartridge in clinic use

Every Felix console placed drives recurring, per-cycle cartridge demand.

- 1 Console placement**
Felix consoles deployed into clinics
- 2 Recurring cartridges**
One single-use cartridge per patient cycle
- 3 Revenue scales**
Recurring revenue grows as clinic usage rises

Quarterly ordering gives clear revenue visibility — and revenue is already being generated across multiple markets.

Multiple levers for expansion



Monash IVF national rollout

Scale from the initial two sites to 22 clinics across Australia.



Global reseller network

Distributors expanding Felix across Europe, MENA and Asia.



New placements & cartridges

Each new console drives recurring cartridge demand.

RICH NEAR-TERM PIPELINE

- Additional Monash IVF volume as adoption grows
- New distribution agreements in advanced talks
- Repeat cartridge orders across MENA and Asia
- Console placements with new clinic groups

A clear line of sight to scale

1

Validated

Clinical trial complete; TGA approval and ARTG listing secured.

2

Deploying

Monash three-month rollout; multi-region contracts; revenue generating.

3

Scaling

National Monash network; reseller-driven cartridge volume.

4

Expanding

New markets and clinic groups; margin expansion at scale.

Proven delivery — contract targets guided in Q4 2025 for end-June 2026 have been met and exceeded (A\$2.5M+ contracted vs the ~A\$2M target).

Revenue building, funding secured

A\$2.5M+

Contracted & locked in to date

A\$106k

Record quarterly revenue (Mar-26)

A\$6M

Targeted contracted revenue, FY27

\$1.2M

Capital raised — recent placement

CAPITAL STRUCTURE · 30 JUNE 2026

Ticker	ASX: MEM
Shares on issue	3,087,233,743 (on settlement)
Share price (2026)	0.6¢ (A\$0.006)
Market cap	~A\$18.5M (at 0.6¢)
Capital raised	\$1.2M placement (firm)
Listed	ASX (Australia)

Peters Investments convertible note (A\$3M face value) extended to 30 June 2027.

SHARE PRICE · ASX: MEM

19 Jan – 19 Jun 2026 · cents per share



Newsflow over the next 12 months

Q3 2026

India CDSCO registration

Submission clears the path to Indian sales (Andro Diagnostics 5-yr supply).

Vietnam regulatory approval

Class B clearance unlocks launch in a new SE-Asian market.

Monash rollout → national

Complete the 3-month deployment, then scale to all 22 clinics.

SEP-26 QTR

First Vietnam orders

Initial commercial orders (~A\$50k) begin to flow.

NEAR TERM

Pivotal trial publication

Peer-reviewed results add independent clinical validation.

ONGOING

New deals & repeat orders

Further distribution agreements; repeat cartridge orders across MENA & Asia.

Experienced board & executive team

BOARD



David Tasker
Chairman

20+ yrs investor relations & capital markets; ex-National Director IR, PPR.



Marjan Mikel
Non-Executive Director
Chair, Commercialisation

25+ yrs MedTech, Pharma & Health;
CEO of Vitasora Health.



Mathew Watkins
Non-Executive Director

Chartered Accountant;
Market Lead, Vistra
Australia (professional services).

EXECUTIVE



Prof. John Aitken
Scientific Director

World-renowned reproductive biologist (Univ. of Newcastle); architect of the Felix science.



A/Prof. Hassan Bakos
Director - Clinical
Engagement & Growth

20+ yrs experience in ART leadership, operations & business development

A new era of commercial execution

Largest deal

Monash IVF national supply agreement

Revenue today

Generated across multiple markets

Recurring model

Cartridge consumables at scale

Global runway

Reseller network + rich pipeline

Validated technology. Signed revenue. A clear path to scale.

Memphasys is entering a new era of commercial execution.

ASX: MEM | memphasys.com.au

Disclaimer

This presentation is not and does not form part of any offer, invitation or recommendation in respect of securities. Any decision to buy or sell Memphasys securities or other products should be made only after seeking appropriate financial advice. Reliance should not be placed on information or opinions contained in this presentation and, subject only to any legal obligation to do so, the Company does not accept any obligation to correct or update them.

This presentation does not take into consideration the investment objectives, financial situation or particular needs of any particular investor.

To the fullest extent permitted by law, Memphasys and its affiliates and their respective officers, directors, employees, agents and advisors accept no responsibility for any information provided in this presentation, including any forward-looking information, and disclaim any liability whatsoever (including for negligence) for any loss howsoever arising from any use of this presentation or reliance on anything contained in or omitted from it or otherwise arising in connection with this presentation.

This presentation provides indicative timelines for various product development and commercialisation activities. These timelines are based on best current estimates, which are subject to change.

All amounts in this presentation are in Australian Dollars (AUD) unless specifically stated otherwise.

The Board has approved these presentation materials.

CONTACT

Investor & media enquiries

INVESTOR & MEDIA RELATIONS

Colin Jacoby

Chapter One Advisors

cjacoby@chapteroneadvisors.com.au · +61 439 980 359

COMPANY

Memphasys Limited

ASX: MEM

www.memphasys.com

MEMPHASYS · ASX: MEM



MEMPHASYS
REPRODUCTIVE BIOTECHNOLOGY

ASX: MEM

www.memphasys.com